A citation-based method for searching scientific literature


List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
263
50

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Antonios Douros, Lisa M Lix, Michael Fralick, Sophie Dell'Aniello, Baiju R Shah, Paul E Ronksley, Éric Tremblay, Nianping Hu, Silvia Alessi-Severini, Anat Fisher,[...]. Ann Intern Med 2020
26
50

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
D F Stroup, J A Berlin, S C Morton, I Olkin, G D Williamson, D Rennie, D Moher, B J Becker, T A Sipe, S B Thacker. JAMA 2000
25

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. BMJ 2009
25

Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments.
Carson Ka-Lok Lo, Dominik Mertz, Mark Loeb. BMC Med Res Methodol 2014
570
25

Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Nicola Fleming, Peter Shane Hamblin, David Story, Elif I Ekinci. J Clin Endocrinol Metab 2020
10
25

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
145
25


Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.
Michael Fralick, Seoyoung C Kim, Sebastian Schneeweiss, Brendan M Everett, Robert J Glynn, Elisabetta Patorno. BMJ 2020
11
25

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
25

Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.
Tanya Wilcox, Christophe De Block, Arthur Z Schwartzbard, Jonathan D Newman. J Am Coll Cardiol 2020
17
25

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
25

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
25

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
25

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Lu Wang, Erica A Voss, James Weaver, Laura Hester, Zhong Yuan, Frank DeFalco, Martijn J Schuemie, Patrick B Ryan, Don Sun, Amy Freedman,[...]. Pharmacoepidemiol Drug Saf 2019
11
25

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun. Sci Rep 2017
86
25

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Robert Puckrin, Marie-Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana H Y Yu, Kristian B Filion. Acta Diabetol 2018
74
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25

Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Young-Gun Kim, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Kwan-Woo Lee, Hae Jin Kim. Diabetes Obes Metab 2018
25
25

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Kelly R Burke, Christine A Schumacher, Spencer E Harpe. Pharmacotherapy 2017
91
25

Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis.
Sruthi Adimadhyam, Glen T Schumock, Gregory S Calip, Daphne E Smith Marsh, Brian T Layden, Todd A Lee. Br J Clin Pharmacol 2019
13
25

Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice.
Hyunah Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim. J Clin Pharm Ther 2020
2
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
25

Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.
Chintan V Dave, Sebastian Schneeweiss, Elisabetta Patorno. Diabetes Obes Metab 2019
32
25

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, David R Matthews. N Engl J Med 2017
98
25

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
25





Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials.
Satoshi Miyashita, Toshiki Kuno, Hisato Takagi, Takehiro Sugiyama, Tomo Ando, Nelson Valentin, Yuichi J Shimada, Masaki Kodaira, Yohei Numasawa, Yumiko Kanei,[...]. Diabetes Res Clin Pract 2020
13
25

Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Sruthi Adimadhyam, Todd A Lee, Gregory S Calip, Daphne E Smith Marsh, Brian T Layden, Glen T Schumock. Diabetes Obes Metab 2018
30
25



Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
34
25




Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
Masafumi Fukuda, Masakazu Nabeta, Takanori Muta, Kei Fukami, Osamu Takasu. Int J Emerg Med 2020
4
25

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation.
Abubakar Tauseef, Muhammad Sohaib Asghar, Maryam Zafar, Noman Lateef, Joseph Thirumalareddy. Cureus 2020
4
25



Diabetic ketoacidosis.
R S Israel. Emerg Med Clin North Am 1989
8
25



Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors.
Yuita Fukuyama, Kenji Numata, Kaede Yoshino, Takushi Santanda, Hiraku Funakoshi. Acute Med Surg 2020
8
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.